Triclabendazole
In today's article, we are going to explore in detail about Triclabendazole, a topic that has captured the attention of millions of people around the world. Triclabendazole is a topic that has generated a great debate in different areas and has aroused great interest in society. Throughout this article, we will analyze different aspects related to Triclabendazole, from its origins to its impact today. We will explore its different dimensions, its relevance today and the implications it has for different sectors. Additionally, we will examine the opinions of experts on the topic, as well as the experiences of people who have been directly affected by Triclabendazole. Without a doubt, this is a fascinating topic that deserves to be explored in depth. Join us on this fascinating journey of discovery about Triclabendazole!
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Fasinex, Egaten, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619048 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Oxidation to sulfone and sulfoxide metabolites |
| Elimination half-life | 22–24 hours |
| Excretion | Feces (>95%), urine (2%), milk (<1%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.127.414 |
| Chemical and physical data | |
| Formula | C14H9Cl3N2OS |
| Molar mass | 359.65 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 175 to 176 °C (347 to 349 °F) |
| |
| |
  (what is this?) (verify) | |
Triclabendazole, sold under the brand name Egaten among others, is a medication used to treat fascioliasis and paragonimiasis.[1] It is very effective for both conditions.[1] Treatment in hospital may be required.[1] It is taken by mouth with typically one or two doses being required.[1]
Side effects are generally few, but can include abdominal pain and headaches.[1] Biliary colic may occur due to dying worms.[2] While no harm has been found with use during pregnancy, triclabendazole has not been studied well in this population.[2] It is a member of the benzimidazole family of medications for worms.[1]
Triclabendazole was approved for medical use in the United States in 2019.[3][4] It is on the World Health Organization's List of Essential Medicines.[5] For human use, it can be obtained from the World Health Organization.[2] It is also used in animals.[6]
Chemistry
It is a member of the benzimidazole family of anthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no carbamate group. Benzimidazoles such as triclabendazole are generally accepted to bind to beta-tubulin therefore preventing the polymerization of microtubules.[7]
History
Since late 1990s, triclabendazole became available as a generic drug, as patents expired in many countries. Many products were developed then. Among them, Trivantel 15, a 15% triclabendazole suspension, was launched by Agrovet Market Animal Health in the early 2000s. In 2009, the first triclabendazole injectable solution (combined with ivermectin) was developed and launched, also by Agrovet Market Animal Health. The product, Fasiject Plus, a triclabendazole 36% and ivermectin 0.6% solution, is designed to treat infections by Fasciola hepatica (both immature and adult liver flukes), roundworms and ectoparasites, as well.[citation needed]
Fasinex is a brand name for veterinary use while Egaten is a brand name for human use.[citation needed]
References
- ^ a b c d e f World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 94, 96. hdl:10665/44053. ISBN 9789241547659.
- ^ a b c Wolfe MM, Lowe RC (2014). "Benzimidazoles". Pocket Guide to GastrointestinaI Drugs. John Wiley & Sons. p. PT173. ISBN 9781118481554. Archived from the original on 20 December 2016.
- ^ "Drug Trials Snapshots: Egaten". U.S. Food and Drug Administration (FDA). 13 February 2019.
- ^ "Egaten (triclabendazole)" (PDF). FDA. Archived from the original (PDF) on 2 October 2019. Retrieved 18 February 2019.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "Triclabendazole". Drugs.com. Archived from the original on 20 December 2016. Retrieved 10 December 2016.
- ^ Baksheeva VE, La Rocca R, Allegro D, Derviaux C, Pasquier E, Roche P, Morelli X, Devred F, Golovin AV, Tsvetkov PO (2025). "NanoDSF Screening for Anti-tubulin Agents Uncovers New Structure–Activity Insights". Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.5c01008.
